Allergy Thera. Share News (AGY)
AGY Share
AGY Share
AGY Share
AGY Share
AGY
AGY Share
AGY Level 2
AGY Live
AGY Broker
AGY Directors
AGY Financial
AGY
AGY Short
AGY
Last checked at -
Mon, 26th Oct 2020 14:17
Allergy Therapeutics PLC - Sussex-based biotechnology firm focused on allergy vaccines - Screens first patient in exploratory field study of Grass MATA MPL immunotherapy on patient who suffer from allergic symptoms when exposed to grass.
Current stock price: 13.29 pence
Year-to-date change: up 30%
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
(Sharecast News) - Allergy Therapeutics updated the market on the financial year just ended on Friday, with the phase one 'Peanut PROTECT' trial, incorporating "ground-breaking" VLP technology, proceeding as planned, with site initiation visits imminent.
Read more(Alliance News) - Allergy Therapeutics PLC on Friday said it expects annual revenue to fall and, while sales are set to improve in the year ahead, it flagged higher costs.
Read more(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:
Read more(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and Tuesday and not separately reported by Alliance News:
Read more(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:
Read moreTRADING UPDATES: Longboat comes up empty; Intercede wins US contract
Read moreAllergy Therapeutics gets US FDA approval for peanut vaccine trial
Read moreTRADING UPDATES: Mobile Streams wins deal; East Imperial revenue jumps
Read moreUK shareholder meetings calendar - next 7 days
Read moreEXECUTIVE CHANGES: GSK adds scientific heft to board ahead of demerger
Read more(Sharecast News) - Biotechnology company Allergy Therapeutics announced positive top-line results from its exploratory field study 'G309' to evaluate the efficacy and safety of its short-course subcutaneous allergen-specific immunotherapy candidate 'Grass MATA MPL'.
Read moreAllergy Therapeutics shares jump on positive G309 trial results
Read moreEARNINGS UPDATES: Harbour Energy enters black; Fonix profit rises
Read moreIN BRIEF: Allergy Therapeutics cheers secondary endpoint results
Read moreIN BRIEF: Allergy Therapeutics study confirms peanut vaccine potential
Read more
Last checked at